Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Altay Biopharma

Altay Biopharma

Altay Biopharma, also known as Altay Therapeutics, is a company that is developing a novel small molecule inhibitor (ALT-CP4) for fibrosis, which targets a cellular protein that regulates matrix deposition and immune activation.

Altay Biopharma, also known as Altay Therapeutics, is a company that is developing a novel small molecule inhibitor (ALT-CP4) for fibrosis, which targets a cellular protein that regulates matrix deposition and immune activation. The company has developed a novel platform that uses primary tissues which represents a more clinically relevant heterogeneous cell population. It is generating gene signatures from each active compound which will allows for assaying for broad changes in gene activation in choosing which small molecule to proceed. Its first clinical lead is idiopathic pulmonary fibrosis (IPF).

Its small molecules have potent inhibitor activity against disease-causing transcription factors by disrupting their association with DNA.

Its novel approach enables the identification of new transcription factors as targets for a wide range of diseases. Using its know-how and robust drug screening approach, it is able to develop potent small molecule drugs targeting disease-causing transcription factors.

Its small molecules have shown exceptional results in several animal models for fibrotic diseases and several cancers.

Timeline

2017
Altay Biopharma was founded by Ali Ozes and Osman Ozes.

Patents

Further Resources

Title
Author
Link
Type
Date

References

Golden logo
By using this site, you agree to our Terms & Conditions.